“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at a drug called barasertib for people with lymphoma
This trial was for people with diffuse large B cell lymphoma (DLBCL) that had continued to grow or came back after chemotherapy.
More about this trial
Doctors usually treat DLBCL with chemotherapy. But if the lymphoma continues to grow or comes back it is more difficult to treat.
Barasertib is a drug that blocks substances (
Barasertib has been used for other types of cancer. But doctors weren’t sure how well it would work for lymphoma.
The aims of this trial were to
- See if barasertib helped people with DLBCL that had continued to grow or came back after chemotherapy
- Look at the side effects of barasertib
Summary of results
The trial team found that barasertib could help people with diffuse large B cell lymphoma (DLBCL).
This was a phase 2 trial.15 people joined the trial.
After their 2nd treatment a PET-CT scan was done to see how well the lymphoma had responded. For 3 people, there was either no sign of their lymphoma (a complete response) or it had shrunk in size (a partial response). For the majority of people their lymphoma stayed the same.
The worst side effects were
- A drop in blood cells
- Feeling or being sick
- Sore mouth
The team concluded this trial showed that targeting an aurora kinase enzyme using barasertib works as a treatment for DLBCL. But because of the limited response of DLBCL to barasertib, it is unlikely to be used by itself. Further trials using barasertib aren’t been planned by the team as it is difficult to give. Also there are other promising drugs to develop.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Chris Hatton
Experimental Cancer Medicine Centre (ECMC)
Oxford Biomedical Research Centre
Oxford University Hospitals NHS Trust